

Hedwig E Deubzer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5322515/publications.pdf>

Version: 2024-02-01

61
papers

4,118
citations

147801

31
h-index

128289

60
g-index

68
all docs

68
docs citations

68
times ranked

7514
citing authors

#	ARTICLE	IF	CITATIONS
1	Bioprinted Cancer Model of Neuroblastoma in a Renal Microenvironment as an Efficiently Applicable Drug Testing Platform. <i>International Journal of Molecular Sciences</i> , 2022, 23, 122.	4.1	12
2	Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 1809-1820.	7.0	22
3	Circulating Cell-Free DNA Assessment in Biofluids from Children with Neuroblastoma Demonstrates Feasibility and Potential for Minimally Invasive Molecular Diagnostics. <i>Cancers</i> , 2022, 14, 2080.	3.7	6
4	Genomic Evolution and Personalized Therapy of an Infantile Fibrosarcoma Harboring an <i>NTRK1</i> Oncogenic Fusion. <i>JCO Precision Oncology</i> , 2022, , .	3.0	4
5	Evidence of neural crest cell origin of a <i>DICER1</i> mutant CNS sarcoma in a child with <i>DICER1</i> syndrome and <i>NRAS</i> mutant neurocutaneous melanosis. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	3.2	4
6	Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against <i>MYCN</i> -amplified neuroblastoma. <i>International Journal of Cancer</i> , 2021, 148, 1219-1232.	5.1	13
7	Clinical Presentation and Management of a Dinutuximab Beta Extravasation in a Patient with Neuroblastoma. <i>Children</i> , 2021, 8, 91.	1.5	2
8	Inhibiting PHGDH with NCT-503 reroutes glucose-derived carbons into the TCA cycle, independently of its on-target effect. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021, 36, 1282-1289.	5.2	8
9	Hemostatic Management in an Infant With Neuroblastoma and Severe Hemophilia B With Extended Half-life Recombinant Factor IX Fusion Protein. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, Publish Ahead of Print, .	0.6	0
10	Germline Mutations Including the Rare Pathogenic Variant c.3206delC in the <i>ATM</i> Gene Cause Ataxia Teleangiectasia-Associated Primary Central Nervous System Lymphoma. <i>Children</i> , 2021, 8, 469.	1.5	2
11	A Reproducible Bioprinted 3D Tumor Model Serves as a Preselection Tool for CAR T Cell Therapy Optimization. <i>Frontiers in Immunology</i> , 2021, 12, 689697.	4.8	25
12	Neuroblastoma Risk Assessment and Treatment Stratification with Hybrid Capture-Based Panel Sequencing. <i>Journal of Personalized Medicine</i> , 2021, 11, 691.	2.5	2
13	Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions. <i>Nature Communications</i> , 2021, 12, 6804.	12.8	39
14	Personalisierte Medizin in der Kinderonkologie: Wo stehen wir heute?. <i>PÄdiatrie Up2date</i> , 2021, 16, 325-342.	0.0	0
15	Transmission of chromosomally integrated human herpes virus-6A via haploidentical stem cell transplantation poses a risk for virus reactivation and associated complications. <i>Bone Marrow Transplantation</i> , 2020, 55, 260-264.	2.4	2
16	Reflection of neuroblastoma intratumor heterogeneity in the new OHC β 1 disease model. <i>International Journal of Cancer</i> , 2020, 146, 1031-1041.	5.1	9
17	Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma. <i>Nature Genetics</i> , 2020, 52, 29-34.	21.4	193
18	The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review. <i>European Journal of Pediatrics</i> , 2020, 179, 191-202.	2.7	55

#	ARTICLE	IF	CITATIONS
19	Sinusoidal Obstruction Syndrome Following Myeloablative Therapy and Tranexamic Acid Treatment for Hemorrhage in Two Patients with Neuroblastoma. <i>Children</i> , 2020, 7, 198.	1.5	0
20	Multiplexed Quantification of Four Neuroblastoma DNA Targets in a Single Droplet Digital PCR Reaction. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1309-1323.	2.8	11
21	Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. <i>European Journal of Cancer</i> , 2020, 136, 52-68.	2.8	42
22	Tumor-Derived Extracellular Vesicles Impair CD171-Specific CD4+ CAR T Cell Efficacy. <i>Frontiers in Immunology</i> , 2020, 11, 531.	4.8	20
23	Central memory phenotype drives success of checkpoint inhibition in combination with CAR T cells. <i>Molecular Carcinogenesis</i> , 2020, 59, 724-735.	2.7	8
24	Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma. <i>Cancer Letters</i> , 2019, 445, 24-33.	7.2	22
25	Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma. <i>Oncotarget</i> , 2018, 9, 2304-2319.	1.8	51
26	Childhood cancer predisposition syndromes—A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 1017-1037.	1.2	200
27	Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival. <i>Cell Death and Disease</i> , 2017, 8, e2635-e2635.	6.3	48
28	2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors. <i>Klinische Padiatrie</i> , 2017, 229, 147-167.	0.6	76
29	Using droplet digital PCR to analyze <i>MYCN</i> and <i>ALK</i> copy number in plasma from patients with neuroblastoma. <i>Oncotarget</i> , 2017, 8, 85234-85251.	1.8	71
30	The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models. <i>Oncotarget</i> , 2017, 8, 6730-6741.	1.8	34
31	RITA displays anti-tumor activity in medulloblastomas independent of <i>TP53</i> status. <i>Oncotarget</i> , 2017, 8, 27882-27891.	1.8	4
32	Minichromosome Maintenance Complex Is a Critical Node in the miR-183 Signaling Network of <i>MYCN</i> -Amplified Neuroblastoma Cells. <i>Journal of Proteome Research</i> , 2016, 15, 2178-2186.	3.7	6
33	<i>MYCN</i> and <i>HDAC5</i> transcriptionally repress <i>CD9</i> to trigger invasion and metastasis in neuroblastoma. <i>Oncotarget</i> , 2016, 7, 66344-66359.	1.8	30
34	Targeting class I histone deacetylase 2 in <i>MYC</i> amplified group 3 medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2015, 3, 22.	5.2	66
35	<i>GRHL1</i> Acts as Tumor Suppressor in Neuroblastoma and Is Negatively Regulated by <i>MYCN</i> and <i>HDAC3</i> . <i>Cancer Research</i> , 2014, 74, 2604-2616.	0.9	54
36	<i>HDAC11</i> is a novel drug target in carcinomas. <i>International Journal of Cancer</i> , 2013, 132, 2200-2208.	5.1	90

#	ARTICLE	IF	CITATIONS
37	Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma. <i>Cancer Cell</i> , 2013, 24, 75-89.	16.8	240
38	Histone deacetylase 10 promotes autophagy-mediated cell survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E2592-601.	7.1	168
39	MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. <i>Nucleic Acids Research</i> , 2013, 41, 6018-6033.	14.5	87
40	Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas. <i>Neuro-Oncology</i> , 2012, 14, 859-869.	1.2	48
41	HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment. <i>Journal of Neuro-Oncology</i> , 2012, 110, 335-348.	2.9	110
42	Nestin Expression Identifies Ependymoma Patients with Poor Outcome. <i>Brain Pathology</i> , 2012, 22, 848-860.	4.1	40
43	A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. <i>Acta Neuropathologica</i> , 2011, 122, 637-650.	7.7	77
44	<i>CAMTA1</i>, a 1p36 Tumor Suppressor Candidate, Inhibits Growth and Activates Differentiation Programs in Neuroblastoma Cells. <i>Cancer Research</i> , 2011, 71, 3142-3151.	0.9	109
45	Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines. <i>Biochemical Pharmacology</i> , 2010, 79, 130-136.	4.4	100
46	Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells. <i>International Journal of Cancer</i> , 2010, 127, 1230-1239.	5.1	36
47	Enhancement of Radiation Response in Osteosarcoma and Rhabdomyosarcoma Cell Lines by Histone Deacetylase Inhibition. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 237-245.	0.8	87
48	HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth. <i>Clinical Cancer Research</i> , 2010, 16, 3240-3252.	7.0	175
49	Histone Deacetylase 8 in Neuroblastoma Tumorigenesis. <i>Clinical Cancer Research</i> , 2009, 15, 91-99.	7.0	335
50	Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 229-238.	2.8	24
51	HDAC family: What are the cancer relevant targets?. <i>Cancer Letters</i> , 2009, 277, 8-21.	7.2	893
52	Targeting of HDAC8 and investigational inhibitors in neuroblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1605-1617.	4.1	64
53	Histone deacetylase inhibitor <i>Helminthosporium carbonum</i> (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells. <i>International Journal of Cancer</i> , 2008, 122, 1891-1900.	5.1	38
54	Anti-neuroblastoma activity of <i>Helminthosporium carbonum</i> (HC)-toxin is superior to that of other differentiating compounds in vitro. <i>Cancer Letters</i> , 2008, 264, 21-28.	7.2	27

#	ARTICLE	IF	CITATIONS
55	Transcription factor AP2alpha (TFAP2a) regulates differentiation and proliferation of neuroblastoma cells. <i>Cancer Letters</i> , 2008, 271, 56-63.	7.2	29
56	Cisplatin-Resistant Neuroblastoma Cells Express Enhanced Levels of Epidermal Growth Factor Receptor (EGFR) and Are Sensitive to Treatment with EGFR-Specific Toxins. <i>Clinical Cancer Research</i> , 2008, 14, 6531-6537.	7.0	48
57	Identification of novel small-molecule histone deacetylase inhibitors by medium-throughput screening using a fluorogenic assay. <i>Biochemical Journal</i> , 2008, 413, 143-150.	3.7	17
58	HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells. <i>Anti-Cancer Drugs</i> , 2008, 19, 849-857.	1.4	24
59	Novel valproic acid derivatives with potent differentiation-inducing activity in myeloid leukemia cells. <i>Leukemia Research</i> , 2006, 30, 1167-1175.	0.8	23
60	Colostrum Obtained from Women Vaccinated with Pneumococcal Vaccine during Pregnancy Inhibits Epithelial Adhesion of <i>Streptococcus pneumoniae</i> . <i>Journal of Infectious Diseases</i> , 2004, 190, 1758-1761.	4.0	25
61	Serotype-Specific Pneumococcal Antibodies in Breast Milk of Gambian Women Immunized With a Pneumococcal Polysaccharide Vaccine During Pregnancy. <i>Pediatric Infectious Disease Journal</i> , 2004, 23, 1023-1029.	2.0	43